InvestorLens

ARWR — ARROWHEAD PHARMACEUTICALS IN

Health Care

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ARWR?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Net accumulation · 4 buying vs 2 selling last quarter
59
Macro Tailwind
Macro conditions are mixed for this sector
53
Why? — Evidence & Confidence ▾

Of 6 tracked investors who changed their ARWR position last quarter, 4 bought and 2 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime).

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin, Steve Cohen, …)
  • +5 tracked investors reported holding ARWR at their latest filing
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About ARROWHEAD PHARMACEUTICALS IN (ARWR)

ARROWHEAD PHARMACEUTICALS IN (ARWR) appears in the most recent 13F filings of 5 tracked institutional investors. ARROWHEAD PHARMACEUTICALS IN is classified in the Health Care sector. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $51M. Across recent filings, tracked investors recorded 10 new positions, 5 increased, 5 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ARWR

60
/100
Institutional Accumulation
Added / Increased15
Reduced5
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track ARWR

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

ARWR Ownership Composition

How ARROWHEAD PHARMACEUTICALS IN is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
84% of tracked value
Institutions
5
tracked investors
Total Reported
$75.2M
combined 13F value
Types3
  • Multi-Strategy / Quant83.8%
  • Value & Distressed14.6%
  • Macro1.6%
Multi-Strategy / Quant(3)
83.8%
Value & Distressed(1)
14.6%
Macro(1)
1.6%

Tracked investors currently reporting ARWR

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    326K
    Value
    $26.6M
    % Portfolio
    0.00%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    407.5K
    Value
    $33.2M
    % Portfolio
    0.01%
  • Howard MarksJun 30, 2026
    Oaktree Capital Management
    Shares
    9.1M
    Value
    $11M
    % Portfolio
    0.15%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    39.9K
    Value
    $3.3M
    % Portfolio
    0.00%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    15K
    Value
    $1.2M
    % Portfolio
    0.00%

Previously held ARWR

These investors reported ARWR in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Ray DalioBridgewater Associates95.6K$6MMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold ARWR?
5 tracked institutional investors disclosed a position in ARWR (ARROWHEAD PHARMACEUTICALS IN) in their most recent 13F filing.
Who is the largest institutional holder of ARWR?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in ARWR, valued at $51M.
Did institutional ownership of ARWR increase or decrease?
Across recent 13F filings, tracked investors recorded 10 new positions, 5 increased, 5 reduced, and 5 fully exited ARWR.
What sector is ARWR in?
ARROWHEAD PHARMACEUTICALS IN is classified in the Health Care GICS sector.
Where does this ARWR ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.